enVVeno Medical Corporation announced the appointment of Jennifer Bright as its new Chief Financial Officer, effective May 19, 2025. Ms. Bright brings over 25 years of extensive financial and strategic leadership experience to the role.
Her background includes working across several commercial-stage medical device and pharmaceutical companies, such as Biolase, Spectrum Pharmaceuticals, Apria Healthcare, Smile Brands, and Teleflex Medical. This experience is highly relevant for enVVeno as it transitions from a development-stage company.
This appointment is expected to strengthen enVVeno's executive leadership team as the company progresses towards potential commercialization of its VenoValve and further development of its enVVe system, enhancing its financial management capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.